Method for Diagnosing Lung Cancer Status and stage
Healthcare and Pharmaceuticals, Telehealth and Care
About The Opportunity:
Lung cancer is the most prevalent cancer in the world with 1.3 million deaths recorded each year. Despite advances in radiology, surgery and chemotherapy, the overall five year survival rate for Lung cancer has changed little over the last 30 years, with only 15% of patients living for five or more years after initial diagnosis.
These poor survival rates are primarily due to its co-morbidities that sometimes prevent early detection, and limit the effectiveness of curative interventions.
Diagnostic methods such as sputum cytology, chest X-ray and computerised tomography (CT scans) are currently being used, however, these methods can have a high false positive rate, and must therefore be combined with follow-up invasive procedures, such as bronchoscopy or a sample tissue biopsy for a definitive diagnosis.
Our technology provides a method for diagnosing and staging Lung Cancer in patients by determining the level of at least one specific bacterial species relative to the level of another bacterial species in a sputum sample.
- Provides earlier diagnosis opportunities.
- The sample is obtained by non-invasive means.
- Healthcare - diagnosis and staging of lung cancers
This technology is protected by a patent application
We are currently seeking partner(s) to further develop this technology